

Newbury Pharmaceuticals is strengthening its portfolio with Buspirone tablets

Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Buspirone tablets.

“Buspirone is a medication for anxiety (anxiolytic) that works by affecting certain natural substances in the brain (neurotransmitters). With the addition of Buspirone we have also secured a new strategic partnership which can be used to source additional new products.” says Mr Lars Minor CEO of Newbury

Regulatory filling will take place in the near time, and we aim to launch this medicine in Sweden and Finland where the total annual value of the market is estimated to be 1,5 MEUR according to DLMI Nordic Pharma Insights.

Newbury currently has more than 30 products in its portfolio and the first launches took place in 2022 with additional launches planned in the years ahead.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[Newbury Pharmaceuticals is strengthening its portfolio with Buspirone tablets](#)